Avivagen Inc.

Expert Comments:

Canadian Life Sciences Firm Seeks Collaborative Cannabis Partner (4/5/19) This represents the company's expansion into another business area. read more >

Large US Market Now Open to Livestock Feed Antibiotic Replacement (3/11/19) Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. read more >

Livestock Feed Developer Partners to Initiate Product Sales in the U.S. (2/22/19) The arrangement represents this Canadian life sciences firm's entrée into a significant market. read more >

Alex Koyfman, Penny Stock Millionaire (2/22/19) "Avivagen Inc. announced earlier this week that it has signed a partnership with CSA Animal Nutrition providing for the sales and distribution of OxC-beta livestock by CSA in the U.S. . .under the terms of the agreement, CSA will coordinate commercial-scale validation research with potential customers and fulfill a sales and distribution role with OxC-beta for poultry, swine and dairy cattle."

Biotech Ramps Up Philippine Sales of Livestock Feed Premix (11/21/18) A distributor of the proprietary product places a third large order. read more >

Life Science Company Addresses Antibiotic Resistance Problem (11/18/18) This firm's proprietary technology provides an alternative to antibiotic use in livestock production. read more >

Three Small-Caps on This Fund Manager's List (10/30/18) Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following. read more >

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed (10/29/18) Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed. read more >

Clive Maund, CliveMaund.com (10/28/18) "Avivagen Inc.'s stock has continued to strengthen, and most importantly it has been impervious to the crashing stock market, which doesn't seem to have affected it at all. The purpose of this update is to draw your attention to this and also to the fact that it appears to be getting ready to break out to the upside, which could happen at any time now. . .we therefore stay long, and it is rated an immediate Strong Buy here."

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers (10/27/18) Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company. read more >

Alex Koyfman, Penny Stock Millionaire (10/26/18) "Avivagen Inc.'s products are tested and have shown to have substantial benefits over existing methodology in an industry that is universally crucial. . .the company's recent progress in signing distribution deals in the Far East illustrates both the demand for the technology and future prospect in markets around the world."

Experts Following This Company

Alex Koyfman, Newsletter Writer – First Call
Clive Maund – CliveMaund.com
	Steve Palmer, President and Chief Investment Officer – AlphaNorth Asset Management

The information provided above is from analysts, newsletters, the company and other contributors.

Avivagen Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.